LifeProof launches LifeJacket case for iPhones
ORLANDO, Fla. — LifeProof has introduced a new protective, waterproof case for the iPhone 4 and iPhone 4S.
The LifeProof LifeJacket, made from high-density foam that is shock, tear and stain resistant, is designed for anyone that uses their iPhone in the water or is looking for increased drop protection, the company said. The buoyant, lightweight case comes in a day-glow orange color to ensure visibility in dense brush or water. What’s more, all buttons and features of iPhone are accessible while in the LifeJacket, including speaker and microphone and features a quick-release lanyard and wrist strap can be attached to eyelets on each corner.
"LifeProof encourages people to live life — to swim, surf, ski, hike, bike or play with the kids, all while staying connected. Boaters, fisherman and swimmers have been clamoring for a way to keep their iPhone close in the water to use apps and stay in touch," LifeProof CEO Gary Rayner said. "The LifeJacket not only floats, but it will protect your iPhone from bump and impacts while rock climbing or accidental drops from great heights."
The LifeProof LifeJacket carries a suggested retail price of $39.99.
Diplomat promotes Atheer Kaddis to SVP sales and marketing
FLINT, Mich. — Diplomat Specialty Pharmacy has promoted its SVP managed markets and clinical services to SVP sales and marketing, the company said Tuesday.
Diplomat said the newly promoted executive, Atheer Kaddis, would report directly to the company’s president, Gary Kadlec. Kaddis preciously worked as director of pharmacy services clinical for Blue Cross Blue Shield of Michigan.
"Atheer is a seasoned professional who has a deep understanding of specialty pharmacy," Kadlec said. "In this new position, Atheer will bring our sales, marketing, business development and trade relations under one authority to allow an agile and seamless response to all the needs of Diplomat’s clients and stakeholders."
Reports: Mylan sues Warner Chilcott over antibiotic drug
NEW YORK — Generic drug maker Mylan is suing Warner Chilcott and an Australian company, alleging that they illegally tried to protect one of their drugs from generic competition, according to published reports.
Reuters reported that Mylan filed a suit against Warner Chilcott and Mayne Pharma Group over the antibiotic and acne drug Doryx (doxycycline), saying they made minor and insignificant changes to the drug so that approval of generic versions would be delayed.
Warner Chilcott markets and sells Doryx in the United States under a license agreement with Mayne, and the drug’s patent expires in 2022. Warner Chilcott has sought to protect Doryx from generic competition since March 2009, when it unsuccessfully petitioned the FDA for a delay in generic approvals. Mayne filed suit against Mylan in the U.S. District Court for the District of New Jersey in May 2009, but the court determined earlier this year that Mylan’s generic version of Doryx did not infringe the drug’s patent, and Mylan launched the drug in May 2012.